The Full Wiki

More info on Ticagrelor

Ticagrelor: Wikis


Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.


From Wikipedia, the free encyclopedia

Systematic (IUPAC) name
CAS number 274693-27-5
ATC code none
PubChem 9871419
Chemical data
Formula C 23H28F2N6O4S 
Mol. mass 522.567 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.  ?
Legal status
Routes oral

Ticagrelor (AZD6140) is a platelet aggregation inhibitor produced by AstraZeneca. The PLATO clinical trial in mid-2009 found that ticagrelor had better mortality rates than clopidogrel (9.8% vs. 11.7%, p<0.001) in treating patients with acute coronary syndrome. Patients given ticagrelor were less likely to die from vascular causes, heart attack, or stroke but had slightly greater chances of major bleeding which was non-significant (11.6 vs. 11.2, p=0.4).[1]

Method of action

Like clopidogrel and ticlopidine, ticagrelor blocks ADP receptors of subtype P2Y12. In contrast to the other antiplatelet drugs, the blockage is reversible. Moreover, it does not need hepatic activation, which could reduce the risk of drug interactions.[2][3]


  1. ^ Wallentin, Lars (August 30, 2009). "Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes". NEJM.  
  2. ^ H. Spreitzer (February 4, 2008). "Neue Wirkstoffe - AZD6140" (in German). Österreichische Apothekerzeitung (3/2008): 135.  
  3. ^ Owen, RT, Serradell, N, Bolos, J (2007). "AZD6140". Drugs of the Future 32 (10): 845–853. doi:10.1358/dof.2007.032.10.1133832.  


Got something to say? Make a comment.
Your name
Your email address